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SHORT COMMUNICATION Open Access
Impact of fasting on 18F-fluorocholine
gastrointestinal uptake and detection of
lymph node metastases in patients with
prostate cancer
Maurits Wondergem1,2*, Friso M. van der Zant1, Remco J. J. Knol1, Jan Pruim3,4 and Igle J. de Jong2
Abstract
Background: 18F-fluorocholine PET/CT is used to detect lymph node metastases in prostate cancer patients.
Physiological 18F-fluorocholine in the gastrointestinal tract, especially in the intestines, may interfere with the
detection of malignant lymph nodes. Fasting is frequently proposed in literature; however, scientific support is
lacking. This study aims to determine the impact of fasting on 18F-fluorocholine uptake in the gastrointestinal tract.
Methods: Eighty patients were studied, 40 fasted for at least 6 h prior to 18F-fluorocholine administration while
the other 40 did not fast. 18F-fluorocholine uptake pattern and intensity were evaluated in the intestine near the
abdominal aorta and four regions near the iliac arteries. 18F-fluorocholine intensity was also measured in the liver,
pancreas, stomach and spleen.
Findings: No statistically significant differences were found in 18F-fluorocholine uptake in the gastrointestinal tract
between the fasting and non-fasting group.
Conclusions: Fasting for 6 h has no effect on 18F-fluorocholine uptake in the gastrointestinal tract. Therefore, no
effects on the detection of malignant lymph nodes are expected, and fasting is not recommended in our opinion.
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Introduction
Choline-PET/CT is widely used in patients with prostate
cancer. Clinically, the imaging technique is used mainly
for restaging of patients with a biochemical relapse and
less frequently for initial staging. One of the strengths of
choline-PET/CT is the detection and localisation of pros-
tate cancer metastases in patients with slightly elevated
PSA. Lymph node metastases can be detected in lymph
nodes, which do not show malignant characteristics on
conventional imaging such as CT and MRI. Patients with
limited lymph node metastases may be selected for proce-
dures with curative intent, while patients with more
extensive disease can be protected from the morbidity of
senseless aggressive therapies.
Detection of lymph node metastases may be hampered
by high physiological choline uptake in the gastrointestinal
tract commonly seen on choline-PET/CT. In the litera-
ture, fasting is frequently proposed before 18F-fluorocho-
line PET/CT, as can be found in a summary of literature
by Chondrogiannis et al. [1]. Four hours of fasting before
administration of 11C-choline is suggested in a document
of the Society of Nuclear Medicine and Molecular
Imaging [2]; however, both the Society of Nuclear
Medicine and Molecular Imaging and the European
Association of Nuclear Medicine have no specific
guidelines for 18F- or 11C-choline PET/CT. To the best of
our knowledge, there is no evidence that supports fasting
prior to choline-PET/CT in order to suppress physio-
logical choline uptake in the gastrointestinal tract. In a
small animal study, fasting was not found to affect tracer
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uptake in the liver for both 11C-choline and 18F-fluorocho-
line [3]. This study aims to determine the impact of
fasting, for at least 6 h, on 18F-fluorocholine uptake in the
gastrointestinal tract.
Methods
From May 2013 data of all 18F-fluorocholine-PET/CTs
at our department were prospectively entered in a data-
base. All patients gave written consent for the use of
their anonymous data. Initially, all patients were scanned
without prior fasting. Due to the observed high physio-
logical 18F-fluorocholine uptake in the intestine, the
patient preparation protocol for prostate cancer patients
was changed after the first 40 patients had been scanned.
In the revised patient preparation protocol, patients were
asked to fast for at least 6 h prior to administration of
18F-fluorocholine. All scans were evaluated after a sec-
ond cohort of 40 patients was scanned that had properly
followed the revised patient preparation protocol.
LIST-mode data of the prostatic region were acquired
for 10 min directly after 18F-fluorocholine administration
(190 MBq, mean), followed by late images from the
inguinal region to the base of the skull approximately
45 min later (Siemens Biograph-16 TruePoint PET/CT,
Siemens Healthcare, Knoxville, USA).
For each patient, the LIST-mode data was used to
determine the choline time-activity pattern in the in-
testine during the first 10 min after 18F-fluorocholine
administration (software: Siemens syngo.via, Siemens
Healthcare, Knoxville, USA). The Kolmogorov-Smirnov
test was used to check for a normal distribution in the
data. A T test or the Mann-Whitney U test was used to
check for the differences between the groups at each time
point after injection. A T test was used when the data in
both groups showed a normal distribution; otherwise, the
Mann-Witney U test was used.
Late data was used to determine the 18F-fluorocholine
uptake in the liver, spleen, stomach, pancreas and intes-
tine. In five different regions: 1 cm or less in the proximity
of the aorta, both the left and right common iliac arteries,
and both the left and right external iliac arteries, intestinal
activity were measured. A T test or the Mann-Whitney U
test was used to check for the differences between the




In both the fasting and non-fasting group, 40 patients
were included. Mean age was 71.9 years (range 59–83)
and 69.1 (range 51–83) for the fasting and non-fasting
Fig. 1 Mean intensity and uptake pattern of 18F-fluorocholine in intestine in the pelvis in the first 10 min after intravenous 18F-fluorocholine
administration in both the fasting and non-fasting group. Error bars showing the standard deviation
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group, respectively. Median PSA was 5.6 (0.3–194) and
4.3 (1.0–43.6), respectively. Indication for 18F-fluorocho-
line PET/CT was primary staging in six patients and
three patients, biochemical relapse in 33 and 37 patients
and other in one patient and zero patients for the fasting
and non-fasting group, respectively.
Early dynamic phase
18F-fluorocholine PET/CT shows a rapid uptake of the
18F-fluorocholine in the intestine in the first 2 min
followed by a more or less stable concentration. No
statistical differences were found between the fasting
and non-fasting groups at any time-point (Fig. 1).
Late phase
In all patients’ intestinal activity, which possibly inter-
fered with lymph node metastases detection, was found
near the aorta, especially in the duodenum. Possible
interfering activity was found near the right common
iliac artery in 65 and 80 % of the patients for the non-
fasting and fasting group, respectively, right external iliac
artery (93 and 98 %) and left external iliac artery (68 and
80 %). Activity near the left common iliac artery was
found less frequently (37 and 45 %). The intensity of
18F-fluorocholine uptake in these regions was not signifi-
cantly different between the fasting and non-fasting
groups (Table 1, Fig. 2). In general, the intestinal activity
near the aorta is higher than in the other regions,
0.003 ≥ p ≥ 0.000 for SUVmax and 0.002 ≥ p ≥ 0.000 for
SUVmean (ANOVA with post hoc Scheffe’s test). No
significant differences were found between the activities
in the other regions.
No significant differences were found in the 18F-
fluorocholine activity uptake in the liver, spleen,
stomach and pancreas between the fasting and the
non-fasting groups (Table 2).
Discussion
The data of our study shows that physiological intestine
activity in the vicinity of the abdominal aorta and iliac
arteries, regions in which lymph node metastases of
prostate cancer are frequently found, is present in all
prostate cancer patients receiving 18F-fluorocholine
PET/CT, especially near the abdominal aorta. In earlier
Table 1 Intensity of 18F-fluorocholine uptake in the intestine in
five perivascular regions in pelvis and abdomen for fasting and
non-fasting group
Fasting Number Mean σ p
SUVmax intestine in region near
Abdominal aorta No 40 5.69 1.43 0.421*
Yes 40 5.25 1.69
Right common iliac artery No 26 3.27 1.79 0.876#
Yes 32 3.25 1.56
Left common iliac artery No 15 4.66 2.48 0.075*
Yes 18 3.64 1.59
Right external iliac artery No 37 3.65 1.50 0.954#
Yes 39 3.58 1.21
Left external iliac artery No 27 3.88 2.05 0.909#
Yes 32 3.50 1.41
SUVpeak intestine in region near
Abdominal aorta No 40 4.91 1.24 0.226*
Yes 40 4.44 1.37
Right common iliac artery No 26 2.78 1.55 0.784#
Yes 32 2.77 1.33
Left common iliac artery No 15 3.98 2.03 0.115*
Yes 18 3.11 1.39
Right external iliac artery No 37 2.93 1.08 0.909#
Yes 39 2.99 1.05
Left external iliac artery No 27 3.14 1.63 0.982#
Yes 32 2.88 1.05
Statistical analysis with *T test and #Mann-Whitney U test
Fig. 2 Example of 18F-fluorocholine PET/CT of a patient from the non-fasting group (a) and a patient from the fasting group (b). The fused images
show transaxial views at the level of the abdominal aorta and the common iliac arteries
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data from our group, we found in 100 patients that the
activity (SUVmax) in malignant lymph nodes and physio-
logical intestine activity does not significantly differ at
both early and late data acquisition time points (Fig. 3,
unpublished). Therefore, interference of physiological
activity in the intestine with detection of lymph node
metastases is realistic.
Most papers on acquisition protocols of 18F-fluorocho-
line deal with the time-point of acquisition and with the
effects of voiding and hydration on detection of lesions
in the prostate. Fasting is regularly proposed in acquisi-
tion protocols without scientific support [1]. Our data
show that the nutritional status has no impact on the
uptake of 18F-fluorocholine in the gastrointestinal tract
and, more specifically, in regions in the gastrointestinal
tract that may interfere with the detection of lymph
node metastases.
The CT part of the PET/CT is important to detect
lymph nodes in areas with high intestinal activity. To
distinguish lymph nodes in these areas, acquisition of
CT images of diagnostic quality with administration of
intravenous iodinated contrast is necessary. Once lymph
nodes are detected on CT, the combination of PET and
CT may distinguish malignant lymph nodes from
physiological lymph nodes, however, especially in small
lymph nodes, characterisation may remain difficult.
Fig. 3 Boxplots of intensity (SUVmax) of
18F-fluorocholine uptake in malignant lymph nodes and intestine in the early and late phase. No statistically
significant difference was found. Early phase p = 0.823 and late phase p = 0.897 (Mann-Whitney U test). Boxplots showing the median, first and third
quartile, maximum and minimal values not considered an outlier and outliers (>1.5 interquartile range)
Table 2 Intensity of 18F-fluorocholine uptake in pancreas, liver,
spleen and stomach for fasting and non-fasting group
Fasting Number Mean σ p
SUVmax
Pancreas No 40 9.39 2.10 0.661*
Yes 40 9.14 2.83
Liver No 40 11.04 2.34 0.165*
Yes 40 11.78 2.39
Spleen No 40 4.72 0.65 0.326*
Yes 40 4.91 1.01
Stomach No 40 7.15 1.79 0.952*
Yes 40 7.12 1.78
SUVpeak
Pancreas No 40 8.41 1.81 0.526*
Yes 40 8.10 2.51
Liver No 40 10.21 2.27 0.128#
Yes 40 10.87 2.19
Spleen No 40 4.25 0.54 0.620#
Yes 40 4.45 0.95
Stomach No 40 6.34 1.74 0.860*
Yes 40 6.27 1.62
Statistical analysis with *T test and #Mann-Whitney U test
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The statistical power may be a shortcoming of the
study. In all regions, the observed differences in the
mean SUVmax and SUVpeak are relatively small in
comparison to the observed standard deviation. One
could suggest that the large study populations would
be needed to exclude the presence of statistically
significant differences. However, in our opinion, the
clinical value of such findings would still be irrele-
vant. Regarding the overlap of found 18F-fluorocho-
line intensity in all intestine regions in both groups
with the intensity in malignant lymph nodes, no
effects on the detection of lymph node metastases
are expected.
Conclusion
Intestinal activity that possibly interferes with the
detection of lymph node metastases is encountered in
all prostate cancer patients receiving 18F-fluorocholine
PET/CT. Fasting for at least 6 h before administration
of 18F-fluorocholine does not influence the uptake of
18F-fluorocholine in the gastrointestinal tract in these
patients. Therefore, fasting is not recommended in
our opinion.
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